Harry Gill, Clinical Associate Professor in Haematology at HKU Medicine, shared a post on X:
” Delighted with the positive interactions with the US FDA moving the Hong Kong-invented ARSENIC TRIOXIDE ORAL SOLUTION (ARSENOL) one step forward to benefit patients with acute promyelocytic leukaemia (APL) worldwide.”
Source: Harry Gill/X
